Intravenous (IV) tissue plasminogen activator (tPA) administration has been shown to be safe and effective for treatment of Acute Ischemic Stroke (AIS) within 3 hours of symptom onset, and newer evidence has shown potential benefit out to 4.5 hours.
StrokeNet, developed by NIH, is the new structure for federal funding of all aspects of stroke research including prevention, acute treatment, and recovery / rehabilitation.
RIA has a rich history of participation in clinical research and innovation dating back to the 1980s. Many of our physicians believe it is important to contribute to science and advance medicine.
The full name of this study is: Barrel™: Study of the Reverse Medical Barrel™ Vascular Reconstruction Device for Adjunctive Treatment to Embolic Coils for Wide-Neck, Intracranial, Bifurcating/Branching Aneurysms.
This is a prospective, multi-center study of patients treated in accordance with the cleared indications for the Penumbra SMART CoilTM System (SMART), Penumbra Coil 400TM (PC 400), and Penumbra Occlusion DeviceTM (POD).
Our neurointerventional surgeons were key contributors to this landmark clinical trial that demonstrated the benefits of endovascular treatment compared to conventional treatment for patients with acute ischemic stroke.
We pride ourselves on contributing to the advancement of medicine and providing patients in the Denver area with the latest screening and treatment alternatives.
